GRIFOLS’ RED-FACED SHAREHOLDERS FINALLY SEE SOME GREENER PASTURES (BUY; 34% UPSIDE)
19/01/23 -" Amidst the volatile markets of the past two years, while Big Pharmas have materially outperformed – thereby regaining their safe-haven status - Smaller Pharmas have been out of favour due to both ..."
Pages
55
Language
English
Published on
19/01/23
You may also be interested by these reports :
02/02/23
Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In ...
02/02/23
Appreciating aprocitentan – How the royalty deal might look like – TP raised to CHF 18.20 (from 15.90) / Add reiterated
02/02/23
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and ...
31/01/23
We have integrated the first set of the 2022 figures. The significantly higher EPS stems mainly from the cancellation of the anticipated CHF-900m ...